Apatinib - 🧡 Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open

Apatinib

Apatinib Afatinib

European Lung Cancer Congress 2022

Apatinib Apatinib Prompts

Apatinib

Apatinib

Apatinib

Apatinib

Apatinib

Apatinib

Apatinib

Apatinib

Introduction Liver cancer is the sixth most prevalent cancer and the fourth leading cause of cancer mortality worldwide in 2018.

  • Xiong: Data curation, supervision, investigation, methodology, writing-review and editing.

  • .

  • This result may be attributed to the smaller sample size of the first-line cohort.

In the exploratory analysis, 54 28.

  • Gu: Data curation, supervision, investigation, methodology, writing-review and editing.

  • Wang: Data curation, supervision, investigation, methodology, writing-review and editing.

  • Treatment was continued until disease progression, presence unacceptable toxicity, withdrawal of consent, investigator decision, or when patients had received camrelizumab for 2 years, whichever occurred first.




2022 denfri.dk.s3-website-eu-west-1.amazonaws.com Apatinib